Aaron Logan, MD, PhD, MPhil
banner
hemedoc.bsky.social
Aaron Logan, MD, PhD, MPhil
@hemedoc.bsky.social
Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, HLH, MRD, post-HCT relapse, GVHD, & immune recon. Photos (Instagram): pyknosis
Reposted by Aaron Logan, MD, PhD, MPhil
This isn't even a slight exaggeration. He is actively working on destroying the US's entire vaccine infrastructure. The HepB vote will be tomorrow, where they will get rid of the birth dose and recommend it at 30 days, dooming a bunch of infants to chronic infection ft. cirrhosis, cancer, and death.
September 18, 2025 at 11:18 PM
Reposted by Aaron Logan, MD, PhD, MPhil
The chair of the #ACIP is a #COVID-contrarian, Martin Kulldorff, as are others on the committee (i.e., Robert Malone). COVID-contrarians also have hands on the lever of vaccine policy at #FDA (i.e., Vinay Prasad, Tracy Beth Hoeg), at #NIH (i.e., Jay Bhattacharya). 1/
September 19, 2025 at 10:15 AM
Reposted by Aaron Logan, MD, PhD, MPhil
9 CDC Directors going back to 1977 speak out. What RFK Jr has done to our nation’s public health system "should alarm every American."

It "is unlike anything we have ever seen at the agency, and unlike anything our country has ever experienced." www.nytimes.com/2025/09/01/o...
Opinion | We Ran the C.D.C.: Kennedy Is Endangering Every American’s Health
www.nytimes.com
September 1, 2025 at 11:23 AM
Imgs from @johnshopkinssph.bsky.social on IG. In my experience, essentially all people want to work when their health allows. But not everyone can find a job. Making monthly work assessments part of maintaining bare minimum health insurance is a ruse to uninsure more Americans. Disgusting.
August 29, 2025 at 3:15 AM
Why work when you can just get sick and be paid to take medications in tRump’s delulu version of America?
Trump: You know, we've cut drug prices by 1200, 1300, 1400, 1,500%. I don't mean 50%. I mean 1400, 1,500%
August 5, 2025 at 3:12 AM
Reposted by Aaron Logan, MD, PhD, MPhil
From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...
US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...
insights.citeline.com
July 26, 2025 at 11:13 PM
Reposted by Aaron Logan, MD, PhD, MPhil
FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers

insights.citeline.com/pink-sheet/a...
July 26, 2025 at 1:57 PM
Sadly, I’ve seen more public evidence in Latin America and Europe that people care about stopping a holocaust than I’ve seen anywhere in America…
#feedpalestine
Hello from Latin America. Just because I'm on vacation doesn't mean that I forget what I care about, so I really appreciate this sign...
July 23, 2025 at 9:12 PM
July 22, 2025 at 3:06 AM
“Working” with ChatGPT is like having an emotionally abusive partner. (Hey OpenAI: the fabrication of references problem has been known for a long time now. Preventing your bot from creating fake references with real PMID numbers that are verifiably wrong with one click should be easy…)
July 6, 2025 at 4:42 PM
Reposted by Aaron Logan, MD, PhD, MPhil
Reminder: Nobel-prize winning PCR (1983), used in basically all genetic tech today, was only possible because of extremophile bacterium discovered in 1964 in Yellowstone funded by a small ~$80k NSF grant with no obvious application at the time. #science 🧪
www.richmondscientific.com/how-a-discov...
How a discovery in Yellowstone National Park led to the development of PCR - Richmond Scientific
A discovery in Yellowstone National Park led to the development of PCR, the gold-standard COVID-19 tests used to fight the global pandemic.
www.richmondscientific.com
June 8, 2025 at 9:09 PM
Reposted by Aaron Logan, MD, PhD, MPhil
Amazing analysis and terrible implications for research in the US. Very impactful research is being eliminated. Worth a look.

The Gutting of America’s Medical Research: Here Is Every Canceled or Delayed N.I.H. Grant www.nytimes.com/interactive/...
Here Are the Nearly 2,500 Medical Research Grants Canceled or Delayed by Trump
Some cuts have been starkly visible, but the country’s medical grant-making machinery has also radically transformed outside the public eye.
www.nytimes.com
June 4, 2025 at 4:58 PM
#ASCO25 is going great so far. I love how walkable Chicago is day and night this time of year. Seriously, if anyone knows a place that has the same vibe and weather as late May in Chicago — but year-round — please let me know, because I want to move there!
May 31, 2025 at 5:26 AM
#ASCO25 Arce-Ruiz: identified ~30K w CH vs 440K wo CH in Biobank DB. Age-related macular degeneration (AMD) appears to be modestly assoc w CH (HR 1.15) but no specific gene mutation indicted as culprit. CH not assoc w vision loss in those with AMD.
May 30, 2025 at 7:25 PM
#ASCO25 #mpnsm Arce-Ruiz: Macular degeneration in pts w clonal hematopoiesis.
May 30, 2025 at 7:21 PM
#ASCO25 #mpnsm Andorsky: Asciminib in 2L CML (wo T315I), n=101, treatment ongoing in 91%. 82.5% achieved BCR-ABL <0.1%, 44% MMR at 24wks. Only 3% had AEs leading to discontinuation. Study ongoing.
May 30, 2025 at 7:19 PM
#ASCO25 #mpnsm Andorsky: Asciminib in 2L treatment of CML (wo T315I). Reason for dc 1L TKI was lack of efficacy in 57% and intolerance 43%.
May 30, 2025 at 7:14 PM
#ASCO25 #mpnsm Mascarenhas: Imetelstat + Ruxolitinib in Int1/2- and HR-MF. Combo well tolerated with low incidence of tcp. Significant redxn in sx burden and spleen size. Also decreased VAF of driver mutations w combo at Imetelstat RP2D.
May 30, 2025 at 7:10 PM
#ASCO25 #mpnsm Mascarenhas: Imetelstat + Ruxolitinib in Int1/2- and HR-MF.
May 30, 2025 at 7:06 PM
#ASCO25 #leusm Goldfinger: Metronomic (weekly) DAC/Ven appears favorable in TP53m MDS/AML vs historical controls (~1/3 of whom recd conventional HMA/Ven). Low rate (12.5%) of febrile neutropenia with metronomic dosing.
May 30, 2025 at 6:52 PM
#ASCO25 #leusm Goldfinger: Metronomic (weekly) DAC/Ven in TP53m MDS/AML. Median OS 11mos. Responses probably (small n) better with monoallelic TP53m.
May 30, 2025 at 6:49 PM
#ASCO25 #leusm Goldfinger: Dosing Decitabine and Ven for terminal differentiation in MDS/AML. Typical dosing relies on TP53 activity. Metronomic dosing (once weekly for both DAC/Ven) may be TP53 independent. Prelim data favorable. Today presenting data on those w TP53m.
May 30, 2025 at 6:46 PM
#ASCO25 #mdssm Daver: Bexmarilimab in HR-MDS has excellent safety profile (13% dc for TEAE, IrAEs in 4%). ORR 72% in 1L, 63% in relapse. Encouraging responses in TP53m setting as well.
May 30, 2025 at 6:42 PM
#ASCO25 #mdssm Daver: Macrophage checkpoint Clever-1 inhibition with Bexmarilimab (w Aza) in HR-MDS. Clever-1 involved in conversion of macrophage to pro-inflammatory phenotype.
May 30, 2025 at 6:39 PM
#ASCO25 #mdssm Garcia-Manero: transfusion independence 76% with Luspa vs 56% with epo with median DOR and 150 vs 95wks. Median OS not NR with Luspa yet vs 46mo with Epo.
May 30, 2025 at 6:35 PM